Now Recruiting: Lymphoma and Leukemia Clinical Trials for Resistant Cancers 

news_10_Artboard 343 copy 7

Three new clinical trials aim to assess the safety and efficacy of a new cancer immunotherapy treatment, KTE-C19, in patients with three types of treatment-resistant blood cancers — refractory aggressive non-Hodgkin lymphoma (NHL), relapsed/refractory mantle cell lymphoma and relapsed/refractory B-precursor acute lymphoblastic leukemia.

Learn more about these new clinical trials here:

Leave a Comment

Your email address will not be published. Required fields are marked *